Navigation Links
Cell Therapeutics Updates Shareholders on Trading
Date:2/11/2009

SEATTLE, Feb. 11 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) announced today that the Borsa Italiana, which is the entity that governs the trading of the Company's common stock on the MTA stock market in Milan, Italy, suddenly suspended trading of the Company's shares in Italy on February 10th. As a result of the suspension of trading by the Borsa Italiana, the security has additionally been halted on the NASDAQ Stock Market pursuant to Marketplace Rule 4120(a)(4) when a security is also registered on a foreign securities exchange and the foreign securities exchange halts trading in such security for regulatory reasons. We have not been advised of any independent basis for NASDAQ's decision to halt trading.

The Company's common stock has traded on the MTA since 2004 and is thus required to comply with the rules and regulations of the Commissione Nazionale per le Societe e la Borsa, or CONSOB, which is the public authority responsible for regulating the Italian securities markets and the Borsa Italiana, which oversees the trading market in Italy. Collectively these agencies regulate companies listed on Italy's public markets. The Company has responded to numerous requests by both the Borsa Italiana and CONSOB to provide additional clarifications about its business operations and financial condition, and the Company has met with CONSOB on several occasions, most recently on February 6th, to answer such questions. As in the past, the Company believes it has complied with CONSOB's requests to issue additional press releases in Italy and if required filed as Form 8-K in the US clarifying the information contained in the Company's SEC filings and press releases and the Company is committed to continuing to do so. The Company is waiting for clarification from the Borsa Italiana and CONSOB as to what additional information or action the Company must take, if any, for the Borsa Italiana to resume trading in Italy. The Company believes that it is currently in compliance with all undertakings for filing and reporting obligations in Italy as agreed with the Borsa Italiana and CONSOB when the shares were accepted for listing in Italy.

The Company is diligently working with the Borsa Italiana, CONSOB and the NASDAQ Stock Market to have one or both markets resume trading in the Company's common stock.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

This press release contains forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect future results. The risks and uncertainties include that the Company may not be able satisfy the Italian regulatory authorities requests for information; the Borsa Italiana may choose not to lift the trading halt in Italy; the Company's current extension of time to comply with the NASDAQ listing requirements may not be extended by the NASDAQ Qualification Panel and the Company may be delisted by NASDAQ; the Company's operating expenses continue to exceed its net revenues and the Company will continue to need to raise capital to fund its operating expenses; as well as other risks listed or described from time to time in the Company's most recent filings with the SEC on Forms 10-K, 8-K and 10-Q. Except as required by law, the Company does not intend to update any of the statements in this press release upon further developments.

     Media Contact:
     Dan Eramian
     T: 206.272.4343
     C: 206.854.1200
     E: media@ctiseattle.com
    http://www.CellTherapeutics.com/press_room

     Investors Contact:
     Ed Bell
     T: 206.272.4345
     Lindsey Jesch
     T: 206.272.4347
     F: 206.272.4434
     E: invest@ctiseattle.com
    http://www.CellTherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Transition Therapeutics Announces Second Quarter Fiscal 2009 Financial Results
2. Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
3. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2009 Financial Results on Wednesday, February 11th, at 4:30 P.M. EST
4. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
5. Nile Therapeutics to Present at the 2009 BIO CEO & Investor Conference
6. Nile Therapeutics to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Merck Serono and Apitope Announce Licensing Agreement on Novel Peptide Therapeutics for the Treatment of Multiple Sclerosis
8. AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics
9. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
10. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
11. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Waltham, Massachusetts (PRWEB) , ... February 17, 2017 ... ... be the leading source of disruptive innovation in the industry, according to the ... Insights Reports are based on surveys of the NEJM Catalyst Insights Council, a ...
(Date:2/18/2017)... MANDEVILLE, La. (PRWEB) , ... February 18, 2017 ... ... Network released today provides the latest information and contact points to easily connect ... including home care, assisted living, and elder-care funding. It also conveys material on ...
(Date:2/17/2017)... ... 2017 , ... For the first time, International Scholarship and ... floor for the 2017 HIMSS Conference & Exhibition at the Orange ... than 40,000 healthcare industry professionals are expected at the conference, where they will ...
(Date:2/17/2017)... Texas (PRWEB) , ... February 17, 2017 , ... ... 8.0 at the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors ... version of the most widely used electronic patient signatures solution in healthcare ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow solution ... February 20 – 22 in San Francisco. As part of the Tri-Conference expo, ... pathology workflow solution, as well as its new precision medicine platform, “Crosswalk Insight: ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , Feb. 17, 2017   Risperdal lawsuits involving ... allegedly associated with use of the atypical antipsychotic medication ... Court of Common Pleas, where the state,s ... program. According to a notice posted on the ... a meeting on March 9, 2017 at 11:00 a.m. ...
(Date:2/17/2017)...   FormFast , the leader in electronic forms ... Engage , one of the largest MEDITECH partners ... will serve as the forms automation and electronic signature ... .  FormFast is a MEDITECH collaborative ... enhance the electronic health record. FormFast,s technology bridges clinical ...
(Date:2/17/2017)... Feb. 17, 2017  BioDigital, Inc., creators of ... of their 3D body mapping technology with eClinicalWorks, ... new integration will be used to capture and ... of the human body. BioDigital pilots show using ... while also increasing the precision of clinical annotations ...
Breaking Medicine Technology: